LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3301-3308

  Zhou, Jundong ^a   Zheng, Bing ^b   Ji, Jiansong ^c   Shen, Fei ^d   Min, Han ^a   Liu, Biao ^a   Wu, Jinchang ^a   Zhang, Shuyu ^e,f  

^a SUZHOU MUNICIPAL HOSPITAL   (China)

^b NANTONG UNIVERSITY   (China)

^c LISHUI UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^f Department of Radiobiology   (China)

Author keywords

Colorectal cancer; KRAS; LYTAK1 and signaling; Transforming growth factor (TGF ) activated kinase 1 (TAK1)

Indexed keywords

APOPTOSIS INHIBITOR; AXIN; BETA CATENIN; CYCLIN D1; ENZYME INHIBITOR; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; LYTAK 1; UNCLASSIFIED DRUG; WNT PROTEIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE CONTROL; HCT116 CELL LINE; HT 29 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; COLORECTAL NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE, INBRED BALB C; MICE, NUDE; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929965350     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2961-2     Document Type: Article

References (22)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, et al. Kras mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18:1–132.
3. Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 2012;13:12153–68.
4. Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol. 2010;17:1168–76.
5. Fakih MM. Kras mutation screening in colorectal cancer: from paper to practice. Clin Colorectal Cancer. 2010;9:22–30.
6. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22:4456–62.
7. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 2012;33:522–30.
8. Martin SE, Wu ZH, Gehlhaus K, Jones TL, Zhang YW, Guha R, et al. Rnai screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors. Curr Cancer Drug Targets. 2011;11:976–86.
9. Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst. 2011;103:1190–204.
10. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell. 2012;148:639–50.
11. Ray DM, Myers PH, Painter JT, Hoenerhoff MJ, Olden K, Roberts JD. Inhibition of transforming growth factor-beta-activated kinase-1 blocks cancer cell adhesion, invasion, and metastasis. Br J Cancer. 2012;107:129–36.
12. Chen MB, Wei MX, Han JY, Wu XY, Li C, Wang J, et al. Microrna-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer. Cell Signal. 2014;26:102–9.
13. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, et al. Deregulation of the PI3k and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120:2858–66.
14. Wang S, Liu Z, Wang L, Zhang X. NF-kappab signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6:327–34.
15. Vaiopoulos AG, Athanasoula K, Papavassiliou AG. NF-kappab in colorectal cancer. J Mol Med (Berl). 2013;91:1029–37.
16. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin Jr AS. NF-kappab controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785–99.
17. McConnell BB, Yang VW. The role of inflammation in the pathogenesis of colorectal cancer. Curr Color Cancer Rep. 2009;5:69–74.
18. Ishizuka M, Nagata H, Takagi K, Kubota K. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg. 2009;250:268–72.
19. Kraus S, Arber N. Inflammation and colorectal cancer. Curr Opin Pharmacol. 2009;9:405–10.
20. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7–G17.
21. Li Q, Verma IM. NF-kappab regulation in the immune system. Nat Rev Immunol. 2002;2:725–34.
22. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000;103:311–20.